Tag - shionogi

 
Menu
Search
 
July 27, 2025
 

Today's print edition

Home Delivery
Subscribe for more access

SHIONOGI

Capsules of Takeda Pharmaceutical's Prevacid heartburn drug. The company's share price dropped by over 5% on Monday after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs.
BUSINESS / Markets
May 12, 2025
Asian pharma stocks tumble on Trump signal to cut U.S. drug prices
The U.S. president's social media post put pressure on drug-related stocks on worries their profits will take a hit if they have to reduce prices in the U.S.
JAPAN / Science & Health
Aug 1, 2023
Japan panel endorses first domestically developed COVID vaccine
The shot is based on the original strain of the coronavirus, making it unlikely that it will be used in Japan or elsewhere.
Japan Times
BUSINESS / Companies
Feb 27, 2023
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
CEO Isao Teshirogi said he expects U.S. approval of the drug could come by the winter of 2024, pending a late-stage trial.
JAPAN / Science & Health
Feb 22, 2023
Shionogi says its drug Xocova may reduce risks of long COVID symptoms
For 14 major symptoms of COVID-19, 14.5% of those given Xocova reported at least one of the symptoms six months after the start of treatment, compared with 26.3% who were given a placebo.
Japan Times
BUSINESS / Companies
Jan 6, 2023
Shionogi's COVID-19 pill may get China approval in March
The Japanese drugmaker has been submitting data to regulators in China and expects Xocova to be authorized for use as early as this quarter, Chief Executive Officer Isao Teshirogi said.
JAPAN / Science & Health
Dec 13, 2022
Shionogi says Japan government to buy 1 million more COVID pill doses
The added supply agreement comes at a time when Japan is dealing with an eighth wave of COVID-19 infections.
Japan Times
JAPAN / Science & Health
Nov 22, 2022
Shionogi COVID-19 pill Xocova wins emergency approval in Japan
A course of Shionogi's treatment consists of seven pills over five days — significantly fewer than alternatives which require between 30 to 40 pills over the same period.
Japan Times
JAPAN / Science & Health
Sep 28, 2022
Shionogi says COVID-19 pill trial shows reduction in symptoms
The drug met the trial's goal of reducing five key symptoms of the omicron variant within 72 hours of onset, the company said.
JAPAN / Science & Health
Jul 20, 2022
Health ministry panel delays decision on emergency approval for Shionogi’s COVID pill
The delay is a blow to one of Japan's largest drugmakers and also raises questions about the process for drugs to gain fast-track approvals in times of emergency.
BUSINESS / Companies
Apr 22, 2022
U.S. in talks with Japan's Shionogi to buy new COVID-19 pill
Shionogi's treatment is in late-stage clinical trials and hasn't yet been authorized, but in earlier studies, it reduced viral loads in patients within the first few days of use.
BUSINESS / Companies
Mar 25, 2022
Shionogi signs supply deal with Japanese government for COVID-19 pill
The government is considering buying a million doses of the drug, pending regulatory approval.
Japan Times
JAPAN / FOCUS
Mar 15, 2022
Japanese firms near domestic rollout of their COVID-19 vaccines
Several companies are expecting to introduce their shots in the coming fiscal year, a major step in Japan reducing its reliance on foreign vaccine manufacturers.
JAPAN
Mar 6, 2022
Shionogi says its COVID-19 shot is effective and safe
The positive data could mean Japan, which is racing to complete a booster drive in hopes of curbing future outbreaks, will soon have an indigenous jab.
JAPAN / Science & Health
Feb 25, 2022
Shionogi seeks approval for Japan’s first domestic COVID pill
Kishida has signaled that the central government will expedite the review process to pave the way for a swift approval if the drug's efficacy and safety are confirmed.
Japan Times
BUSINESS
Dec 27, 2021
Tardy COVID-19 vaccine makers under fire for trials in developing nations
Vaccine developers at the testing phase now are seeking developing countries where vaccination rates remain low and the virus is still active.
JAPAN / Explainer
Oct 20, 2021
Oral drug molnupiravir seen as 'trump card' in Japan's battle against COVID-19
The treatment developed by Merck could receive fast-track approval by the end of the year, and other oral drugs to fight the coronavirus are not far behind.
Japan Times
BUSINESS / Companies
Oct 8, 2021
COVID-19 pill sales could hit $2 billion, drugmaker Shionogi says
Competition to snag a piece of the COVID pill market is fierce, as the world adjusts to the virus being endemic.
Japan Times
BUSINESS
Dec 11, 2020
Why Japan is largely a spectator in the coronavirus vaccine race
A total of 52 vaccine candidates were in clinical evaluation worldwide as of Tuesday, of which only one was Japanese.
Japan Times
JAPAN / Science & Health
Oct 29, 2020
Japan's Shionogi readies COVID-19 vaccine for December trial
The firm plans to put its vaccine candidate into Phase 1 clinical trials in December and shift into Phase 2 by January.
BUSINESS / Companies
Jun 22, 2020
Japan drugmaker to tie up with universities to develop new test method for coronavirus
Japanese pharmaceutical company Shionogi & Co. said Monday that it will collaborate with universities in the country to put into practical use a new testing method for the novel coronavirus.
Tokyo is the No. 2 choice for international students
The University of Tokyo. International students are increasingly flocking to Asia, with affordability being a particularly important metric.
Junglia, Japan’s newest theme park, opens in northern Okinawa
In Junglia’s Dinosaur Safari attraction during a media preview on Thursday, a casual drive through a habitat for the prehistoric creatures goes haywire when several Tyrannosaurus rexes break out of containment.
Extreme heat grips Japan, including even Hokkaido
The city of Obihiro in Hokkaido amid scorching heat on Thursday
‘Demon Slayer’ movie slashes its own box office records
“Demon Slayer: Kimetsu no Yaiba Infinity Castle” is the first installment in a trilogy that's set to wrap the anime adaptation of Koyoharu Gotoke's manga about sword-wielding heroes fighting man-eating demons.
Ishiba rules out joint document on U.S. tariffs as deal's details trickle out
Prime Minister Shigeru Ishiba delivers a speech at an event in Karuizawa, Nagano Prefecture, on Friday afternoon.
Behind the scenes: Inside Fuji Rock’s strategy for staying on top
In recent years, Fuji Rock has had fewer blockbuster performers and showcased more top-selling Japanese acts and international musicians' first-time performances in Japan.
Tokyo is the No. 2 choice for international students
The University of Tokyo. International students are increasingly flocking to Asia, with affordability being a particularly important metric.
Hall of Fame always held deeper meaning for Ichiro
Ichiro presents then-Hall of Fame President Jeff Idelson with the bat he used to break the single-season hits record in 2004.
Japan leans into homegrown AI amid rising competition
McKinsey’s 2025 Technology Trends Outlook, published Wednesday, says that the use of “sovereign AI” is a trend gaining significant global traction, including in Japan.
JT picks: What not to miss at Fuji Rock 2025
Fuji Rock Festival turns the green slopes of Niigata Prefecture’s Naeba Ski Resort into a summer escape that offers soundtracks for every mood.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

Ichiro Suzuki, one of the most iconic players in NPB and MLB history, was elected to the Baseball Hall of Fame with 99.7% of the vote.
With Hall of Fame induction, Ichiro makes himself heard loud and clear
By Jason Coskrey

SUSTAINABLE JAPAN

Looking ahead to Yokohama’s Green × Expo 2027
Looking ahead to Yokohama’s Green × Expo 2027

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER